

## Freedom of Information Request: Our Reference CTMUHB\_244\_20

### You asked:

Please can you send me the following information?

	<b>FOI Question</b>	<b>Number of Patients</b>	<b>Initiating department</b> <i>e.g. rheumatology, dermatology, etc.</i>
1	How many patients (in the Health Board) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?		
2	How many patients (in the Health Board) have been initiated on biosimilar adalimumab?		
	- and what is the split by brand in the last 12 months for the following products?		
	o Amgevita		
	o Imraldi		
	o Hulio		
	o Hyrmioz		
	o Idacio		
3	How many patients have been initiated on these products?		
	o guselkumab (Tremfya)		
	o risankizumab (Skyrizi)		
	o brodalumab (Kyntheum)		
	o ixekizumab (Taltz)		

Clarification provided on the 8<sup>th</sup> August - Please can you send me the data for the financial year 1<sup>st</sup> April 19 – 31<sup>st</sup> March 20 (but the 1<sup>st</sup> April 20 – 31<sup>st</sup> July 20 dates would be fine if this would be easier for you).

### Our response:

The data provided in the table below relates to patients treated with biologic therapy for the period 1<sup>st</sup> April 2019 to 31<sup>st</sup> March 2020 (financial year 19/20). Due to the way data is collected this is the latest 12 month period of data available. Unfortunately, we are unable to provide data that crosses Financial Years.

	<b>FOI Question</b>	<b>Number of Patients</b>	<b>Initiating department</b> <i>e.g. rheumatology, dermatology, etc.</i>
1	How many patients (in the Health Board) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?	82 36	Rheumatology Gastroenterology
2	How many patients (in the Health Board) have been initiated on biosimilar adalimumab?	39 17	Rheumatology Gastroenterology

	- and what is the split by brand in the last 12 months for the following products?		
	○ Amgevita	9 17	Rheumatology Gastroenterology
	○ Imraldi	30	Rheumatology
	○ Hulio	0	
	○ Hyrmioz	0	
	○ Idacio	0	
3	How many patients have been initiated on these products?		
	○ guselkumab (Tremfya)	0	
	○ risankizumab (Skyrizi)	0	
	○ brodalumab (Kyntheum)	0	
	○ ixekizumab (Taltz)	0	

Cwm Taf biologic service for Dermatology is provided in a tertiary centre at Cardiff and Vale University Health Board. Therefore you may wish to redirect this element of your request to [CAV\\_FOI.Requests@wales.nhs.uk](mailto:CAV_FOI.Requests@wales.nhs.uk)